Nodular Vasculitis That Developed during Etanercept (Enbrel) Treatment in a Patient with Psoriasis.
- Author:
Seung Bae PARK
1
;
In Kyu CHANG
;
Myung IM
;
Young LEE
;
Chang Deok KIM
;
Young Joon SEO
;
Jeung Hoon LEE
Author Information
- Publication Type:Case Report
- Keywords: Etanercept; Psoriasis; Vasculitis
- MeSH: Adult; Biopsy; Cicatrix; Diagnosis; Erythema; Follow-Up Studies; Humans; Injections, Subcutaneous; Latent Tuberculosis; Leg; Mycobacterium tuberculosis; Necrosis; Panniculitis; Psoriasis*; Recurrence; Skin; Tuberculosis; Tumor Necrosis Factor-alpha; Vasculitis*; Etanercept
- From:Annals of Dermatology 2015;27(5):605-607
- CountryRepublic of Korea
- Language:English
- Abstract: Nodular vasculitis was introduced by Montgomery for cases of erythema induratum-like lesions that were not associated with tuberculosis. Nodular vasculitis has been associated with both nontuberculous infections and noninfectious conditions. However, there has been no report on the development of nodular vasculitis during tumor necrosis factor-alpha inhibitor treatment. A 28-year-old man visited our clinic for the treatment of severe psoriasis with a 20-year history. Subcutaneous injection of etanercept (25 mg, twice weekly) was started. One year later, erythematous nodules developed on his lower leg. A skin biopsy showed lobular panniculitis with extensive necrosis and vasculitis. To exclude latent tuberculosis, an assay specific for Mycobacterium tuberculosis antigens was performed, with a negative result. After stopping etanercept under the diagnosis of nodular vasculitis associated with etanercept, the lesions gradually disappeared, leaving depressed scars in 3 months. There has been no recurrence after 6 months of follow-up.
